These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37045504)

  • 1. Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Lee SH; Jeong YH; Hong D; Choi KH; Lee JM; Park TK; Yang JH; Hahn JY; Choi SH; Gwon HC; Jeong MH; Kim BK; Joo HJ; Chang K; Park Y; Ahn SG; Suh JW; Lee SY; Cho JR; Her AY; Kim HS; Kim MH; Lim DS; Shin ES; Song YB;
    JACC Cardiovasc Interv; 2023 Apr; 16(7):829-843. PubMed ID: 37045504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
    Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
    Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
    Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
    Johnson SG; Gruntowicz D; Chua T; Morlock RJ
    J Manag Care Spec Pharm; 2015 Jul; 21(7):552-7. PubMed ID: 26108379
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Tunehag KR; Thomas CD; Franchi F; Rossi JS; Keeley EC; Anderson RD; Beitelshees AL; Duarte JD; Gong Y; Kerensky RA; McDonough CW; Nguyen AB; Ortega-Paz L; Venkatesh S; Wang Y; Johnson JA; Winterstein AG; Stouffer GA; Angiolillo DJ; Cavallari LH; Lee CR
    J Am Heart Assoc; 2024 Jun; 13(12):e033791. PubMed ID: 38874073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet Function and Genotype after DES Implantation in East Asian Patients: Rationale and Characteristics of the PTRG-DES Consortium.
    Her AY; Jeong YH; Kim BK; Joo HJ; Chang K; Park Y; Song YB; Ahn SG; Suh JW; Lee SY; Cho JR; Kim HS; Kim MH; Lim DS; Shin ES;
    Yonsei Med J; 2022 May; 63(5):413-421. PubMed ID: 35512743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of CYP2C19 genotyping and clinical outcomes following percutaneous coronary intervention in East Asian patients treated with oral P2Y
    Xi Z; Wang Y; Lu Q; Qiu H; Gao Y; Gao A; Gao R
    Thromb Res; 2023 Aug; 228():85-93. PubMed ID: 37301117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.
    Zhang M; Wang JR; Zhang Y; Zhang P; Ren MY; Jia XM; Ma LP; Gao M; Hou YL
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10753-10768. PubMed ID: 33155236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
    EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention].
    Wu Y; Zhang XX; Tian L; Jiang JJ; Xu L; Huang YL; Liu H; Li YS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):377-385. PubMed ID: 28511321
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
    Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
    JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-percutaneous coronary intervention CYP2C19 genotyping in an Irish population: The potential role in identifying clopidogrel therapy-related bleeding risks.
    Soh BWT; Cusack R; Waters M; O'Connor C; Arnous S; Kiernan T
    Br J Clin Pharmacol; 2023 Aug; 89(8):2413-2422. PubMed ID: 36890711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
    Ozawa T; Suda M; Ikegami R; Takano T; Wakasugi T; Yanagawa T; Tanaka K; Ozaki K; Hirono S; Minamino T
    Int Heart J; 2018 Jan; 59(1):21-26. PubMed ID: 29279531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects of clopidogrel resistence and CYP2C19 genotype on the clinical prognosis of patients with acute coronary syndrome undergoing percutaneous coronary intervention].
    He CB; Li Q; Ye YC; Zhao XL; Tu CC; Zeng Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Sep; 48(9):765-771. PubMed ID: 32957760
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
    Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes After Percutaneous Coronary Intervention Over Time on the Basis of CYP2C19 Polymorphisms.
    Zhang Y; Zhao X; Ye Y; Li Q; Zeng Y
    J Cardiovasc Pharmacol; 2022 Feb; 79(2):183-191. PubMed ID: 34711749
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Osama S; Wirth F; Zahra G; Barbara C; Xuereb RG; Camilleri L; Azzopardi LM
    Drug Metab Pers Ther; 2021 Jan; 37(2):155-161. PubMed ID: 34851561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of low-dose prasugrel on platelet reactivity and cardiac dysfunction in acute coronary syndrome patients requiring primary drug-eluting stent implantation: A randomized comparative study.
    Kitano D; Takayama T; Fukamachi D; Migita S; Morikawa T; Tamaki T; Kojima K; Mineki T; Murata N; Akutsu N; Sudo M; Hiro T; Hirayama A; Okumura Y
    Catheter Cardiovasc Interv; 2020 Jan; 95(1):E8-E16. PubMed ID: 30983087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.
    Sheng XY; An HJ; He YY; Ye YF; Zhao JL; Li S
    J Clin Pharm Ther; 2022 Aug; 47(8):1112-1121. PubMed ID: 35396752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.